CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s second-half surge in approvals made 2008 the agency’s best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation.
You may also be interested in...
What Innovation Crisis? First-In-Class Drug Approvals Stable For Almost 25 Years, FDA Says
An FDA study evaluating NMEs by level of innovation finds level first-in-class approvals to be consistent, and approvals after the study period reinforce “encouraging” findings. Analysis says new metric should be basis for assessment of programs created by FDASIA to speed development of innovative products.
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.